Covid-19
Brazil turns down request to vaccinate children, adolescents with COVID vaccines
Brazilian Health Regulatory Agency, Anvisa, said it turned down a request by the Brazilian Butantan Institute for approval of Chinese CoronaVac to vaccinate children aged between 3 and 17.
Anvisa stated this on Wednesday that the request was not approved due to lack of sufficient data.
The Instituto Butantan biologic research centre is producing CoronaVac.
“Vaccination of children and teenagers with CoronaVac vaccine is not approved. It was impossible to prove the vaccine’s efficacy and safety for this age group, based on information by the Butantan Institute.
READ ALSO: Actress drops bombshell, advises people not to take COVID vaccines
“Data on immunogenicity leave unclear the duration of protection provided by the immunizing agent,” said Anvisa.
The agency also noted that there was no conclusion on side effects or vaccine efficacy among children with associated diseases, chiefly due to the insufficient number of tests’ participants.
Only the Pfizer/BioNTech vaccine has so far been approved by Anvisa for vaccinating people over 12 years old in Brazil.
However, the Janssen laboratory has received a permit to conduct experiments with children under 18 in the Latin American country
-
Latest1 week agoLagos NURTW organising secretary Toba Ajiboye dies after gunmen attack
-
Business5 days agoCBN targets $12bn annual Diaspora inflows to boost FX liquidity
-
Business5 days agoSEC launches nationwide campaign to help investors recover unclaimed dividends
-
Business3 days agoNigerian AI researcher champions ethical artificial intelligence at COPA AI 2026 summit in Wales
-
Latest1 week agoOyo APC berates Makinde over call for UN probe into Oriire school rescue
-
Business5 days agoCBN launches real-time FX tracker for BDCs, tightens oversight of FX market
-
Business5 days agoFood prices now biggest threat to inflation, beyond CBN’s reach – Analysts
-
Latest6 days agoKwankwaso calls for renewed North–South-East Political alliance ahead of 2027


